Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
madcow...
You sound like my buddy, Frank Caliendo, doing his George Bush impression.
OMR made a nice move at days end, hope a few others were in on it.
Have a great weekend,
10nis
OMR....
Finds $500 million worth of gold and silver. There take will end up being 80-90% so roughly $400 - $450 million. The company is currently trading at a market cap of $325 million... OMR also has two other findings that are expected to be announced in the next quarter or two that could be worth an additional $150+ million. It looks like a interesting trade.
10nis
DNDN....
Management should be fired for not raising cash when they could have in the mid-teens. Instead of raising some dirt cheap cash (raise $50-100 million selling 3-7 million shares) they sold their own shares to hedge their bets while riding shareholders dreams. Just plain stupid, IMO.
Happy trading/investing,
10nis
Takeover...
What is your estimate of the 2008 take-out price?
Thanks,
10nis
<<< The timing of the new shelf—on the eve of the quarterly CC—has me wondering. It could mean nothing… or it could be at attempt to clear the decks for another news item Thursday morning.>>>
What potential news item do you think it could be Thursday morning, if anything? Japanese partnership?
Just curious on your thoughts....
10nis
premarket...
For once I was able to take advantage of premarket. I just bought back in the $7.09-7.15 range. Nice little morning profit for little or no work. IDIX is definitely oversold.
10nis
EU Rubber Stamp....
Do you think the pre-market 10+% move is warranted? FWIW, I sold some in premarket in order to lock-in a 10+% gain as I don't see why the news is worth the move. Will plan on buying back later this week, hopefully, at a lower price.
10nis
MEDI.........
http://biz.yahoo.com/rb/070422/medimmune_astrazeneca.html?.v=3
Reuters
AstraZeneca near deal to buy MedImmune: report
Sunday April 22, 11:57 pm ET
NEW YORK (Reuters) - Britain's AstraZeneca Plc (LSE:AZN.L - News) is near a deal to buy U.S. biotechnology company MedImmune Inc. (NasdaqGS:MEDI - News) in a transaction that could be worth more than $13 billion, the Wall Street Journal reported on its Web site on Sunday.
The deal could be announced on Monday morning, the paper reported, citing unidentified sources.
MedImmune said earlier this month that it had hired Goldman Sachs (NYSE:GS - News) to explore a sale. The group said it decided to seek bids following indications of interest by big drugmakers and dissatisfaction over the stock price performance among some investors.
It has been the subject of takeover speculation for some time, with talk of a bid intensifying since billionaire investor Carl Icahn disclosed in February he owned 2.8 million shares of the company.
AstraZeneca, which is hungry for assets to refill a depleted new drugs pipeline, was considered a possible suitor at the time.
MedImmune, one of the larger independent biotech firms in the United States, is best known as the maker of the nasal spray flu vaccine FluMist, but it also has two other marketed products, Synagis for infectious respiratory disease and Ethyol for reducing chemotherapy side effects.
MedImmune and AstraZeneca could not immediately be reached for comment.
MNOV
Anyone have any thoughts/comments on MNOV?
TIA,
10nis
Go seek....
No worries. I was just trying to understand from a high level why there was a large market cap difference and Dew answered it as always. Dew should really charge for his services!!
I'm a complete novice and will always be when it comes to understanding the science/technical aspects of the world of biotech/drugs. I'm on the accounting/finance side of things so I mainly look for market capitalization differences between competing companies and potential end-markets and try and understand from a high level why they exist - which is why I'm here.
10nis
VRTX news is out....
http://biz.yahoo.com/bw/070414/20070414005015.html?.v=1
Press Release Source: Vertex Pharmaceuticals Incorporated
Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C
Saturday April 14, 12:05 pm ET
-- PROVE 1 data support potential to shorten treatment duration in treatment-naive, genotype 1 HCV patients --
BARCELONA, Spain--(BUSINESS WIRE)--In a late-breaker presentation at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), researchers today presented data from a planned interim analysis of the PROVE 1 clinical trial, which is the first trial to evaluate short-duration therapy with the investigational hepatitis C protease inhibitor telaprevir (TVR, VX-950) in combination with pegylated interferon (peg-IFN) and ribavirin (RBV) in treatment-naive, genotype 1-infected hepatitis C patients. The data from PROVE 1 demonstrated a high rate of rapid viral response (RVR) in the telaprevir groups and a low rate of on-treatment viral breakthrough, and suggested that 12 weeks of telaprevir-based therapy enabled some patients to clear the virus. Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX - News) is developing telaprevir in collaboration with Tibotec.
"The high rates of RVR observed in the telaprevir groups in PROVE 1, and the fact that some patients have remained persistently viral negative 20 weeks after stopping the 12 weeks of telaprevir-based therapy, suggest that we may be able to shorten the treatment duration in genotype 1 HCV patients," said John McHutchison, M.D., Principal Investigator for the PROVE 1 study and Director of Gastroenterology and Hepatology Research at Duke Clinical Research Institute. "These interim results are encouraging and suggest that high sustained viral response (SVR) rates may be achieved with regimens that are 24 weeks in total duration. We look forward to 24 week follow-up data from the initial group of patients who stopped treatment at 12 weeks, and follow-up data from patients in the study who received 24 weeks of treatment."
PROVE 1 Summary
88% and 79% of patients receiving telaprevir achieved a rapid viral response (RVR) as measured by plasma HCV RNA (less than)30 IU/mL and (less than)10 IU/mL, respectively, at 4 weeks.
Six of 9 patients in one treatment arm who completed 12 weeks of treatment, and who had achieved an RVR as defined by the study protocol ((less than)10 IU/mL), continued to have undetectable HCV RNA 20 weeks after stopping all treatment ("SVR20").
The treatment discontinuation rate due to adverse events through 12 weeks was 11% in telaprevir arms and 3% in the control arm. Rash, gastrointestinal events and anemia were the most common events leading to discontinuation in the telaprevir arms.
"These interim results support our approach to evaluating telaprevir-based regimens of differing durations in our Phase 2 program. The results of the 12-week duration regimen provide a level of confidence in the shorter duration approach, and we look forward to safety and antiviral data, including SVR data, from the 24-week telaprevir-based regimens," said John Alam, M.D., Executive Vice President, Medicines Development, and Chief Medical Officer of Vertex. "The information from PROVE 1 and PROVE 2 should allow us to design optimized durations and regimens for Phase 3 development."
PROVE 1 and PROVE 2 represent two of three large, ongoing clinical studies of telaprevir. In aggregrate, the three studies are designed in part to evaluate the safety and antiviral activity of different durations of telaprevir-based therapy in genotype-1 infected HCV treatment-naive and treatment-failure patients, both with and without ribavirin. Taken together, the PROVE studies are expected to provide information to optimize the treatment duration and treatment regimen for telaprevir-based therapy.
PROVE 1: Implications for Clinical Development and Registration Path
Vertex today discussed the potential implications that the new information from PROVE 1 has for future clinical development of telaprevir. Vertex stated its intention to consider evaluation of treatment regimens that would include telaprevir in combination with peg-IFN and RBV, and depending on PROVE 2 data, regimens that may exclude RBV. Vertex expects to focus on treatment durations of no more than 24 weeks. Vertex and Tibotec are planning to meet with regulatory authorities to discuss the Phase 3 design in mid-2007 and are planning to initiate Phase 3 clinical development in the fourth quarter of 2007. The registration strategy and timing of an NDA filing will be dependent on discussions with regulatory authorities.
PROVE 1 Results at EASL
Interim 12-week antiviral analysis of PROVE 1
A total of 250 patients were enrolled in PROVE 1 and received at least one dose of telaprevir or placebo in addition to Peg-interferon alfa-2a (peg-IFN) + ribavirin (RBV) in the study. A total of 175 patients received at least one dose of telaprevir in 1 of 3 arms (treatment arms B, C and D) and 75 patients received at least one dose of placebo (arm A). Treatment with telaprevir resulted in a high proportion of patients achieving a rapid viral response at 4 weeks. At the time of the interim analysis, all patients had either completed 12 weeks or discontinued from the study prior to week 12. Available 4-week and 12-week results are detailed in the following table:
Interim HCV RNA results for Patients Enrolled in the PROVE 1 Trial
---------------------------------------------------------------------
Treatment Assignment Patients Patients Patients Patients
with with with with HCV
HCV RNA HCV RNA HCV RNA RNA (less
(less (less (less than)10
than)30 than)10 than)10 IU/mL at
IU/mL IU/mL IU/mL end of 12
at end at end at end weeks of
of 4 of 4 of 12 dosing
weeks weeks weeks (last on-
of of of treatment
dosing dosing dosing, value
DC=F carried
(a) forward)
---------------------------------------- -------- -------- ----------
TVR + peg-IFN + RBV (arms B, C 153 of 138 of 123 of 149 of 175
and D) 175 175 175 (85%)
(88%) (79%) (70%)
---------------------------------------- -------- -------- ----------
Placebo + peg-IFN + RBV (arm A) 12 of 75 8 of 75 29 of 75 32 of 75
(16%) (11%) (39%) (43%)
---------------------------------------- -------- -------- ----------
(a) Intent-to-treat, discontinuation=failure analysis. Patients who
had HCV RNA (less than)10 IU/mL at the time of discontinuation are
counted as "failures", however these patients will be followed post-
discontinuation to determine if they achieve a sustained viral
response (SVR).
---------------------------------------------------------------------
In PROVE 1, a low rate of viral breakthrough was observed. Viral breakthrough occurred in 12 patients receiving telaprevir (7%), all but one of which occurred in the first 4 weeks of treatment.
Analysis of PROVE 1 Patients who Finished All Treatment at 12 Weeks
Seventeen of 175 patients received at least one dose of telaprevir in "Arm D" of the PROVE 1 study (telaprevir + peg-IFN + RBV). According to the study protocol, patients in Arm D were eligible to stop all treatment at week 12 if they met on-treatment criteria, including the achievement of RVR ((less than)10 IU/mL at week 4) and maintenance of this viral response ((less than)10 IU/mL) at week 10 of treatment. Nine of 17 patients met these criteria and stopped therapy at 12 weeks, and 6 of these patients continued to have undetectable HCV RNA at week 20 of post-treatment follow-up. Of the remaining 8 patients enrolled in Arm D, 4 discontinued due to adverse events prior to week 12, and 4 did not achieve RVR.
Interim 12-Week Safety Analysis of PROVE 1
In PROVE 1, the types of adverse events that have been commonly observed with interferon and ribavirin were seen across all treatment arms. The most common adverse events, regardless of treatment assignment, were fatigue, rash, headache and nausea. Gastrointestinal disorders, rash and anemia were more common in the telaprevir arms.
In the telaprevir dosing arms, the incidence of treatment discontinuations due to adverse events through 12 weeks was 11% (19 of 175 patients), compared to 3% (2 of 75 patients) in the control arm. The difference between the two groups is due to the greater number of discontinuations due to rash, gastrointestinal disorders and anemia in the telaprevir arms compared to the control arm. The most common reason for treatment discontinuation in the telaprevir arms was rash (7 patients), and the median time to discontinuation in these patients was 64 days.
Webcast of Investor Presentation
Vertex intends to provide a live webcast of its investor presentation from Barcelona beginning at 7:30 p.m. CEST (1:30 p.m. EDT) on Saturday, April 14. The presentation may be accessed from the 'Events Calendar' on the homepage of Vertex's website at www.vrtx.com. A replay of the webcast will also be available on the Company's website until April 27, 2007. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
IDIX vs. ITMN
Is there any good reason why IDIX trades around a $300 million market cap while InterMune Inc. trades around $800 million?
TIA,
10nis
ACHN...
I don't own any. Did it really fall from $20 in February to $6 and change now? I'll have to spend some time looking at it this weekend if you think its worth some time.
10nis
""How is the Fed ever going to be able to lower rates if our economy keeps growing and adding new jobs? Shame on you Mr. Bush..stop growing the economy!! The government announced this morning that the unemployment rate dropped to 4.47% and that 180,000 new jobs were created. That was up from the anticipated 135,000 new jobs. Where are the big layoffs from the housing bubble burst? Of course the possibility exists that there will be a lag time before the housing slowdown affects the employment numbers. I know the critics will say that they are not GOOD jobs..Sure many are service jobs..but think about it we would only need additional service jobs if we needed more services? Meaning things must be growing..you cannot get a better job before you have a job.""
First of all, Bush has helped grow the economy??? I guess sending 250-350k troops to Iraq has helped expand the economy as well as wasting, I mean spending $500+ billion a year on weapons was another brillant way to expand the economy. However, our stupid I mean highly educated president has done nothing to generate real growth in the economy. The insane liquidity in the market is driving the growth and you can thank Mr. Greenspan, the Japanese & Chinese for that. What happens when the Japs and Chinese stop buying our debt or demand higher rates?
The jobs report is just U.S. Government fuzzy math. You say we would only need additional service jobs if we needed more services??? What new services are we providing??? We're adding jobs in the same services because Chipotle, Kohl's/Target/American Eagle, etc., are expanding. Those are fine jobs.... I think they pay about $8-9/hr.
Also, what is this talk about getting a better job? Who is getting a better job? If I'm not mistaken 90+% of the new jobs (180k) were service related jobs in the past month. How do you export services to the rest of the world?
In addition, the construction sector isn't being properly recorded as the two hottest construction areas (AZ, FL) in America used a LOT of illegals. Construction in FL alone is down 30+% vs. 2006 and 2006 was down approximatetly 30+% from 2005. Also, its estimated that approximately 40-50% of all construction companies that existed in FL in 2005 will no longer exist by the end of 2007.
Last, I think its very possible that a large percentage of the job growth is the result of companies reclassifying illegals as regular employees making it appear as there's been new job growth when in fact there was no growth at all. But that's just based on talking to a few executives in the PEO arena.
10nis
P.S..... Why is everyone looking for a Fed rate cut? Oil's at $64+/barrel, demand vs. supply factors are only pointing to higher prices for the majority of commodities, the Chinese want higher returns on their U.S. Treasury purchases, etc. IMO, the only way the Fed cuts rates from current levels is if some horrific event or economic meltdown forces them too.
LMRA....
Nice reasoning.... Present at a conference and stock price goes higher. Sounds like a new consulting service McKinsey or Bain should start selling.
Have a great weekend,
10nis
Ex-CFO....
Seems like a promotion to me. I also wonder if Mr. Arkowitz saw the writing on the wall (i.e., NVS will eventually purchase the rest of IDIX) and decided it makes the most sense to leave now versus wait for something better. I don't see his departure as a negative to IDIX. Mr. Arkowitz is completely replaceable.
10nis
TSO....
Try the 10k shares of TSO are worth $1m vs. $100m. I need to get one of your calculators. Fuzzy math my friend!!
10nis
Give up on SIRI and buy some GTCB instead...
10nis
Dew....
Can you permanently remove Spice is rice from these boards? He/she adds absolutely nothing.
Thanks,
10nis
BEC purchasing BSTE at a 53+% premium to its Friday's closing price.
http://biz.yahoo.com/prnews/070325/clsu018.html?.v=3
Press Release Source: Beckman Coulter, Inc.
Beckman Coulter to Acquire Biosite Incorporated
Sunday March 25, 5:31 pm ET
- Creates Leading Position in U.S. Immunoassay Market Segment, Complementing Established Leadership Positions in U.S. Chemistry and Hematology Segments
- Combines Extensive Installed Base of Clinical Lab Systems with Top Developer of Novel Immunoassay Tests
- Expands Beckman Coulter's Served Market to "Near-Patient" Testing and Extends Geographic Reach for Biosite's Products
- Transaction Expected to Immediately Accelerate Revenue Growth, Improve Operating Margins and be Accretive to GAAP Earnings in 2008 and Beyond
FULLERTON, Calif. and SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- Beckman Coulter, Inc. (NYSE: BEC - News), a leading developer, manufacturer, and marketer of products that simplify, automate, and innovate complex biomedical tests, and Biosite® Incorporated (Nasdaq: BSTE - News), a leading biomedical company commercializing proteomics discoveries for the advancement of medical diagnosis, announced today that they have entered into a definitive merger agreement under which Beckman Coulter will acquire all of Biosite's outstanding common stock in a cash tender offer of $85.00 per share, or approximately $1.55 billion on a fully diluted share basis. The proposed transaction is expected to immediately accelerate Beckman Coulter's revenue growth, improve operating margins and be accretive to GAAP earnings in 2008 and beyond.
Scott Garrett, Beckman Coulter's President and Chief Executive Officer, said, "This is an exciting transaction that grew out of our successful relationship with Biosite over the past four years in the area of B-type Natriuretic Peptide (BNP), a test that aids in the diagnosis, risk stratification and assessment of severity of heart failure and the risk stratification of patients with acute coronary syndromes. It will position Beckman Coulter as a leading provider of immunoassay tests, especially within cardiac diagnostics. Biosite utilizes third-party distributors, and more than 85% of sales come from within the United States. A major source of value in the transaction is our ability to leverage our global commercial infrastructure and installed base to expand sales of Biosite's immunoassay tests, including BNP. Longer term, we will have significant opportunities to leverage Biosite's pipeline of novel diagnostic tests across our large installed base of automated systems in hospital laboratories. Additionally, the transaction will expand our offerings into near-patient testing, providing additional markets for many of our highest-value tests."
Biosite's Chairman and Chief Executive Officer, Kim Blickenstaff, stated, "We have enjoyed a close relationship with Beckman Coulter, and together we can enhance our delivery of high value diagnostic solutions that improve clinical and economic outcomes for acute diseases. Our focus is clearly aligned with Beckman Coulter's dedication to improving patient health and reducing the cost of care. Beckman Coulter's reputation and global infrastructure will be instrumental in expanding the market opportunity for our Triage® family of diagnostic products around the world. Our board of directors believes that this transaction is in the best interest of our shareholders, employees and other stakeholders and has unanimously voted to recommend that Biosite shareholders tender their shares in this offer."
Scott Garrett added, "We expect the transaction to be accretive to GAAP earnings in 2008, and we remain on track to achieve our full year 2007 outlook, as stated in our February 8 earnings release, excluding any impact from the Biosite acquisition. We expect significant revenue growth resulting from the improved effectiveness of our global commercial franchise selling BNP along with other cardiac markers. Biosite will bring to Beckman Coulter an entrepreneurial culture and talented workforce recognized for product and market development. Everyone at Beckman Coulter looks forward to expanding our collaboration with the Biosite team in San Diego and elsewhere, as we maintain and grow the center of excellence that Biosite has established."
Beckman Coulter will promptly commence a tender offer for all of Biosite's outstanding common stock. The offer is conditioned upon at least a majority of the outstanding Biosite shares, determined on a fully diluted basis, being tendered, as well as the satisfaction of regulatory and other customary conditions. Approval of the transaction by Beckman Coulter's shareholders is not required. It is currently expected that the transaction will close in the second quarter of 2007.
Advisors
Morgan Stanley is acting as financial advisor to Beckman Coulter in connection with the acquisition and is serving as dealer manager for the proposed tender offer. Goldman Sachs is acting as financial advisor to Biosite. Financing for the transaction has been fully committed by Morgan Stanley and Citigroup. Latham & Watkins, LLP is serving as legal counsel to Beckman Coulter and Cooley Godward Kronish LLP is serving as legal counsel to Biosite.
Investor Webcast Event
Beckman Coulter will host a webcast on Monday, March 26, 2007, at 8:30 am ET to discuss the transaction. The audio portion of the event may be accessed by dialing (877) 516-3365 or (706) 679-3246 and asking for the Beckman Coulter conference call or reservation #3687656.
To participate via the website and obtain access to the presentation materials, please go to Beckman Coulter's website at www.beckmancoulter.com and select "go to IR" under Investor Relations and find the call listed under "What's Ahead". The webcast will be archived for future on-demand replay.
GAPPER - CLAY & QID
INSM...
The workforce cut (i.e., restructure) was the result of the INSM's litigation settlement with Tercica and DNA (over Patent infringement). INSM didn't fall because of cutting workers but because the Company lost the litigation with Tercica and DNA. Wall Street tends to look favorably at companies that cut costs except when a Company has to in order to remain a going concern.
10nis
INSM...
Layoffs was the reason for the fall in INSM?? You people are crazy. This is what happened...
Insmed Announces Restructure, Settlement Ending IPLEX(TM) Patent Dispute
Wednesday March 7, 10:51 am ET
Restructure Improves Financial Position and Allows Company to Focus on Clinical Development for HIV-Related Condition and Myotonic Muscular Dystrophy
RICHMOND, Va.--(BUSINESS WIRE)--Insmed Inc., (NASDAQ: INSM - News) announced today that it has restructured its operations as a result of the litigation settlement with Tercica Inc. (NASDAQ: TRCA - News) and Genentech Inc. (NYSE: DNA - News), which was announced yesterday, ending all litigation between the parties.
In its restructuring, Insmed's sales and marketing group will be eliminated and production at Insmed's manufacturing site in Boulder, Colorado will be scaled back, to reflect the reduced drug product requirement. The Company anticipates that the current workforce of 150 will be reduced by approximately 34% as a result of the restructure. The projected savings are expected to extend the Company's current cash reserves and allow the Company to fund its operations into the fourth quarter of 2007. As of December 31, 2006 Insmed had $24.1 million of cash on hand.
Geoffrey Allan Ph. D., President, CEO and Chairman of Insmed, commented: "With the lawsuit behind us we can now focus all our efforts on developing IPLEX for the promising indications we have already identified, and with the License and Development agreement with Tercica and Genentech in place we believe we are well positioned for success." Dr. Allan added that, "The end of litigation removes a cloud from the Company's future and the consequent restructuring allows for an improved financial position."
The Company is presently conducting ongoing clinical research in patients with HIV associated Adipose Redistribution Syndrome (HARS) and Myotonic Muscular Dystrophy (MMD). The clinical trial for HARS is ongoing at the University of California, San Francisco while the MMD clinical trial is ongoing at the University of Rochester. Initial data from both trials is expected to be released in Q2 2007.
AGEN....
Insider buying - A token purchase of 50k shares at $1.80/sh or whatever... That's not what I call strong insider buying. When will AGEN need to raise more cash? Good Luck with your trading.
10nis
Werber/IDIX report...
I say someone like Dew should send Werber's IDIX report to a few of his superiors at Citi highlighting the pathetic mistakes... I bet he wouldn't last more than a few weeks. BS is one thing.... however, someone making a few hundred k's in a year should at a minimum have the general facts straight. Either cover the company correctly or don't give any damn coverage.
Dew for President!!
10nis
COR...
Anyone know what is driving this higher today? Was something said at the Roth Conference?
TIA,
10nis
CC at 8:00AM ET? Is this earlier than normal? Maybe they don't want the participants/analysts on the call to be awake or they have something interesting to say before the markets open.
Did anyone buy any CORI when I recommended it?
CORI...
OVTI is going much higher, IMO. WFC is the ultimate and equals $2-$3 in EPS in FY 2008-2009. OVTI is sitting on $6.50 of cash and no debt. Looks like OVTI is heading back to the $30's again.
10nis
Glad to see IDIX moving as well.
OVTI.... Has news today.
Where's Dew been the past few days? I hope all is alright with him.
10nis
CORI....
Lots of volume moving into it today.
Nice up volume today...
News coming or just smart money getting back into the stock? I guess the previous post answered my question... Technical buying for now.
10nis
Strong volume day...
GTCB is seeing some strong volume today relative to the past few weeks. Hopefully any major sellers have officially left the building.
10nis
New Chief Medical Officer (PR)....
What are everyone's thoughts on the change in CMO? TIA.
Press Release Source: Idenix Pharmaceuticals, Inc.
http://biz.yahoo.com/prnews/070108/clm207.html?.v=1
Idenix Pharmaceuticals, Inc. Announces Appointment of Douglas Mayers, M.D. as Executive Vice President and Chief Medical Officer
Monday January 8, 5:00 pm ET
CAMBRIDGE, Mass., Jan. 8 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX - News) today announced the appointment of Douglas Mayers, M.D. to the position of executive vice president and chief medical officer. Reporting to Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix, Dr. Mayers will be responsible for the company's clinical development activities. Dr. Mayers will replace Nathaniel Brown, M.D., who is resigning as an executive officer, but remaining affiliated with Idenix as a Senior Medical Advisor. The transition of the role of chief medical officer will occur at the end of January.
"Dr. Mayers' nearly 20 years of medical and clinical development experience in infectious diseases will be important as we seek to advance our hepatitis C and HIV clinical programs and to expand our pipeline with additional clinical drug candidates," said Dr. Sommadossi. "We are delighted to have Dr. Mayers join the senior management team of Idenix."
Dr. Sommadossi added, "I want to thank Dr. Brown for his valuable contributions to Idenix. Under his leadership, we successfully developed telbivudine for the treatment of hepatitis B from phase I through FDA approval in just six years and significantly advanced our hepatitis C clinical program. We look forward to continuing our working relationship with Dr. Brown."
Prior to joining Idenix, Dr. Mayers was International Head/Vice President, Therapeutic Area of Virology with Boehringer Ingelheim for five years and was responsible for the strategic coordination of all HIV and hepatitis clinical trials in phases I through IV. Prior to joining industry, Dr. Mayers conducted clinical trials in HIV research during his seventeen years in the Navy and his subsequent three years as the Head of Infectious Diseases with Henry Ford Hospital. Board certified in internal medicine and infectious diseases, Dr. Mayers completed his M.D. at the University of Pennsylvania. Dr. Mayers remains in the Navy Reserves and currently holds the rank of Captain.
Not a trick question....
Question is for average number of posts during....2007!!
TELK....
Just curious whether you're long calls or the stock? For something with a known timeline like results before year-end or at worst some time in January, why not buy some February calls?
I'm debating straddling TELK on Tuesday assuming that results aren't announced before the market opens.
Happy Holidays,
10nis
Xrymd what am I missing re GTCB?
Daved....Why do you keep asking the same questions? Dew already answered your question at least a couple of times. If you don't believe his answer call the company. Enough said... Also, if you're not interested in GTCB then drop the repeated questions and go research some other company as your questions are getting a bit annoying.
Peace,
10nis
VRTX / IDIX.......
VRTX latest results should be good for IDIX.
10nis